290 related articles for article (PubMed ID: 24670685)
1. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.
Pathiraja TN; Nayak SR; Xi Y; Jiang S; Garee JP; Edwards DP; Lee AV; Chen J; Shea MJ; Santen RJ; Gannon F; Kangaspeska S; Jelinek J; Issa JP; Richer JK; Elias A; McIlroy M; Young LS; Davidson NE; Schiff R; Li W; Oesterreich S
Sci Transl Med; 2014 Mar; 6(229):229ra41. PubMed ID: 24670685
[TBL] [Abstract][Full Text] [Related]
2. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Stone A; Valdés-Mora F; Gee JM; Farrow L; McClelland RA; Fiegl H; Dutkowski C; McCloy RA; Sutherland RL; Musgrove EA; Nicholson RI
PLoS One; 2012; 7(7):e40466. PubMed ID: 22808167
[TBL] [Abstract][Full Text] [Related]
4. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
Choi HJ; Lui A; Ogony J; Jan R; Sims PJ; Lewis-Wambi J
Breast Cancer Res; 2015 Jan; 17(1):6. PubMed ID: 25588716
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
7. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
Lui AJ; Geanes ES; Ogony J; Behbod F; Marquess J; Valdez K; Jewell W; Tawfik O; Lewis-Wambi J
Cancer Lett; 2017 Jul; 399():29-43. PubMed ID: 28411130
[TBL] [Abstract][Full Text] [Related]
8. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
Zhang J; Zhou C; Jiang H; Liang L; Shi W; Zhang Q; Sun P; Xiang R; Wang Y; Yang S
Cell Death Dis; 2017 Apr; 8(4):e2732. PubMed ID: 28383555
[TBL] [Abstract][Full Text] [Related]
9. SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer.
Perone Y; Farrugia AJ; Rodríguez-Meira A; Győrffy B; Ion C; Uggetti A; Chronopoulos A; Marrazzo P; Faronato M; Shousha S; Davies C; Steel JH; Patel N; Del Rio Hernandez A; Coombes C; Pruneri G; Lim A; Calvo F; Magnani L
Nat Commun; 2019 May; 10(1):2115. PubMed ID: 31073170
[TBL] [Abstract][Full Text] [Related]
10. ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
Si X; Liu Y; Lv J; Ding H; Zhang XA; Shao L; Yang N; Cheng H; Sun L; Zhu D; Yang Y; Li A; Han X; Sun Y
Oncotarget; 2016 Apr; 7(15):20966-80. PubMed ID: 26980709
[TBL] [Abstract][Full Text] [Related]
11. A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer.
Nayak SR; Harrington E; Boone D; Hartmaier R; Chen J; Pathiraja TN; Cooper KL; Fine JL; Sanfilippo J; Davidson NE; Lee AV; Dabbs D; Oesterreich S
Horm Cancer; 2015 Dec; 6(5-6):214-24. PubMed ID: 26113056
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.
Hiken JF; McDonald JI; Decker KF; Sanchez C; Hoog J; VanderKraats ND; Jung KL; Akinhanmi M; Rois LE; Ellis MJ; Edwards JR
Oncogene; 2017 Apr; 36(16):2319-2327. PubMed ID: 27869171
[TBL] [Abstract][Full Text] [Related]
13. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
[TBL] [Abstract][Full Text] [Related]
15. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
16.
Yu J; Zhang X; Ma Y; Li Z; Tao R; Chen W; Xiong S; Han X
Cancer Biother Radiopharm; 2021 Feb; 36(1):95-105. PubMed ID: 32552008
[No Abstract] [Full Text] [Related]
17. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
[TBL] [Abstract][Full Text] [Related]
18. Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.
Ward E; Varešlija D; Charmsaz S; Fagan A; Browne AL; Cosgrove N; Cocchiglia S; Purcell SP; Hudson L; Das S; O'Connor D; O'Halloran PJ; Sims AH; Hill AD; Young LS
Clin Cancer Res; 2018 Aug; 24(15):3692-3703. PubMed ID: 29567811
[No Abstract] [Full Text] [Related]
19. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
[TBL] [Abstract][Full Text] [Related]
20. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Selli C; Turnbull AK; Pearce DA; Li A; Fernando A; Wills J; Renshaw L; Thomas JS; Dixon JM; Sims AH
Breast Cancer Res; 2019 Jan; 21(1):2. PubMed ID: 30616553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
